Antibody Drug Conjugate Market Analysis:
Various factors are adding to the global antibody
drug conjugate market share. These factors, as per the new MRFR report, include
advances in medical technology, rising cases of cancer, growing obese
population, and increasing aging population. Additional factors adding market
growth include increasing collaborations between biotechnology companies,
biopharmaceuticals, and research institutes, rising R&D on oncology
diseases, increasing research on advanced drug discoveries, rising number of
research on antibody therapies, and preclinical research.
The global Antibody
Drug Conjugate Market Growth is
likely to grow at a 19% CAGR between
2017- 2023, reveals the new Market
Research Future (MRFR) report. Antibody drug conjugates are new-age therapeutic
agents that have three parts- a chemical linker to attach cytotoxic agents to
antibodies, cytotoxic agents for killing target cancer cells, and specific
antibodies for binding. Lymphoma, multiple myeloma, breast cancer, solid
tumors, skin cancer, ovary cancer, colon cancer, lung cancer, glioblastoma,
pancreas cancer, kidney cancer, prostate cancer, leukemia, and others are some
of its key applications. The different antibody drug conjugates include
drug/toxin, linker, and monoclonal antibodies, to name a few.
On the contrary, shortage of funds & high
procedure prices are factors that are likely to impede the global antibody drug
conjugate market growth during the forecast period.
Competitive Analysis:
Vaccinex Inc (U.S.),
Antikor (U.K), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.),
Genentech (U.S.), Roche Holding AG (Switzerland), ImmunoGen, Inc.(U.S.), and
Seattle Genetics (U.S.)
Market Segmentation:
·
The MRFR report
provides an inclusive segmental analysis of the antibody drug conjugate market
by end user, application, technology, product, and type.
·
Based on type, the
antibody drug conjugate market has been segmented into drug/toxin, linker,
monoclonal antibodies, & other types.
·
Based on
application, the market for antibody drug conjugate has been segmented into
solid tumors, skin, lymphoma, multiple myeloma, cancer, colon cancer, lung
cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate
cancer, leukemia, and others.
·
By product, the
antibody drug conjugate market has been segmented into adcertis, kadcyla, &
other products.
·
By technology, the
global antibody drug conjugate market has been segmented into ImmunoGen
technology, immunomedics technology, Seattle genetics technology, and
others.
·
By end user, the
antibody drug conjugate market is segmented into biopharmaceutical companies,
biotechnology companies, academic research institutes, specialized cancer
centers, hospitals, and others.
Regional Analysis:
Based on the region, the global antibody drug
conjugate market covers the recent trends and growth opportunities across
Europe, the Asia Pacific (APAC), the Americas, and the Middle East and Africa
(MEA). Of these, the Americas will have the lions share in the market over the
forecast period for increasing healthcare awareness and rising prevalence of
cancer.
The antibody drug conjugate market in Europe is
predicted to have healthy growth over the forecast period for the huge
population being affected by cancer. Besides, the government is focussing on
R&D to develop new drugs to offer citizens the best treatment.
The antibody drug conjugate market in the APAC
region is predicted to grow at a fast rate over the forecast period due to increasing
prevalence of cancer in India & China.
The antibody drug conjugate market in the MEA is
predicted to have steady growth over the forecast period.
NOTE : Our team of researchers are studying
Covid19 and its impact on various industry verticals and wherever required we
will be considering covid19 footprints for a better analysis of markets and
industries. Cordially get in touch for more details.
Comments
Post a Comment